All In Biotech

Drug Trial Radar · NCT01287039

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 489 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

489

Actual

Start

Apr 2011

Primary completion

Dec 2013

Study completion Mar 2014

Sponsor

Sponsor type
Industry
First posted
Feb 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.

Conditions

  • Eosinophilic Asthma

Interventions

  • ReslizumabDrug

    Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.

  • PlaceboDrug

    Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of TreatmentTime frame: Day 1 to Week 52
  2. Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs)Time frame: Day 1 to Week 52

Locations

128 sites in 17 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 58

    Scottsdale, Arizona

  • Teva Investigational Site 61

    Los Angeles, California

  • Teva Investigational Site 37

    Orange, California

  • Teva Investigational Site 56

    San Diego, California

  • Teva Investigational Site 34

    Colorado Springs, Colorado

  • Teva Investigational Site 52

    DeBary, Florida

  • Teva Investigational Site 55

    Miami, Florida

  • Teva Investigational Site 18

    Valrico, Florida

  • Teva Investigational Site 49

    Lexington, Kentucky

  • Teva Investigational Site 65

    Louisville, Kentucky

  • Teva Investigational Site 51

    Boston, Massachusetts

  • Teva Investigational Site 74

    St Louis, Missouri

  • Teva Investigational Site 35

    Missoula, Montana

  • Teva Investigational Site 64

    Boys Town, Nebraska

  • Teva Investigational Site 68

    Rochester, New York

  • Teva Investigational Site 60

    The Bronx, New York

  • Teva Investigational Site 30

    Winston-Salem, North Carolina

  • Teva Investigational Site 31

    Cincinnati, Ohio

  • Teva Investigational Site 62

    Columbus, Ohio

  • Teva Investigational Site 50

    Oklahoma City, Oklahoma

  • Teva Investigational Site 66

    Altoona, Pennsylvania

  • Teva Investigational Site 32

    Nashville, Tennessee

  • Teva Investigational Site 63

    Boerne, Texas

  • Teva Investigational Site 72

    Houston, Texas

  • Teva Investigational Site 38

    Richmond, Virginia

  • Teva Investigational Site 33

    Madison, Wisconsin

  • Teva Investigational Site 641

    Clayton, Australia

  • Teva Investigational Site 644

    Daw Park, Australia

  • Teva Investigational Site 642

    Frankston, Australia

  • Teva Investigational Site 645

    Liverpool, Australia

  • Teva Investigational Site 643

    Nedlands, Western Australia, Australia

  • Teva Investigational Site 261

    Brussels, Belgium

  • Teva Investigational Site 264

    Brussels, Belgium

  • Teva Investigational Site 260

    Ghent, Belgium

  • Teva Investigational Site 262

    Jambes, Belgium

  • Teva Investigational Site 263

    Liège, Belgium

  • Teva Investigational Site 160

    Rancagua, Chile

  • Teva Investigational Site 163

    Santiago, Chile

  • Teva Investigational Site 164

    Santiago, Chile

  • Teva Investigational Site 165

    Santiago, Chile

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.